Vertex Pharmaceuticals Inc. (NASDAQ:VRTX) SVP Paul M. Silva sold 5,062 shares of the company’s stock in a transaction that occurred on Thursday, November 10th. The shares were sold at an average price of $90.98, for a total transaction of $460,540.76. Following the completion of the sale, the senior vice president now directly owns 17,125 shares of the company’s stock, valued at approximately $1,558,032.50. The sale was disclosed in a filing with the Securities & Exchange Commission, which is accessible through this link.

Vertex Pharmaceuticals Inc. (NASDAQ:VRTX) opened at 94.42 on Tuesday. Vertex Pharmaceuticals Inc. has a 52-week low of $73.31 and a 52-week high of $134.71. The company’s market capitalization is $23.42 billion. The company’s 50-day moving average is $83.48 and its 200-day moving average is $89.56.

Vertex Pharmaceuticals (NASDAQ:VRTX) last posted its quarterly earnings data on Tuesday, October 25th. The pharmaceutical company reported $0.16 earnings per share (EPS) for the quarter, missing the Zacks’ consensus estimate of $0.18 by $0.02. The firm had revenue of $413.78 million for the quarter, compared to analysts’ expectations of $423.53 million. Vertex Pharmaceuticals had a negative return on equity of 5.31% and a negative net margin of 13.45%. Vertex Pharmaceuticals’s revenue was up 33.6% compared to the same quarter last year. During the same period in the prior year, the firm earned ($0.13) earnings per share. On average, analysts expect that Vertex Pharmaceuticals Inc. will post $0.78 earnings per share for the current fiscal year.

Insider Buying and Selling by Quarter for Vertex Pharmaceuticals (NASDAQ:VRTX)

VRTX has been the subject of several recent analyst reports. JMP Securities reaffirmed a “buy” rating on shares of Vertex Pharmaceuticals in a research note on Tuesday, August 16th. Stifel Nicolaus lowered their target price on shares of Vertex Pharmaceuticals from $108.00 to $105.00 and set a “buy” rating for the company in a research note on Tuesday, August 16th. Zacks Investment Research raised shares of Vertex Pharmaceuticals from a “hold” rating to a “buy” rating and set a $98.00 target price for the company in a research note on Wednesday, July 20th. Jefferies Group reaffirmed a “buy” rating and issued a $107.00 target price (up previously from $102.00) on shares of Vertex Pharmaceuticals in a research note on Sunday, July 31st. Finally, JPMorgan Chase & Co. reaffirmed a “buy” rating on shares of Vertex Pharmaceuticals in a research note on Sunday, July 31st. Fourteen equities research analysts have rated the stock with a hold rating and fourteen have assigned a buy rating to the stock. Vertex Pharmaceuticals has an average rating of “Buy” and an average price target of $108.63.

A number of institutional investors have recently bought and sold shares of VRTX. Mycio Wealth Partners LLC increased its position in Vertex Pharmaceuticals by 1.5% in the second quarter. Mycio Wealth Partners LLC now owns 1,218 shares of the pharmaceutical company’s stock worth $105,000 after buying an additional 18 shares in the last quarter. Conning Inc. increased its position in Vertex Pharmaceuticals by 0.3% in the second quarter. Conning Inc. now owns 5,740 shares of the pharmaceutical company’s stock worth $494,000 after buying an additional 20 shares in the last quarter. Municipal Employees Retirement System of Michigan increased its position in Vertex Pharmaceuticals by 0.3% in the third quarter. Municipal Employees Retirement System of Michigan now owns 7,820 shares of the pharmaceutical company’s stock worth $682,000 after buying an additional 20 shares in the last quarter. Northwestern Mutual Investment Management Company LLC increased its position in Vertex Pharmaceuticals by 0.3% in the second quarter. Northwestern Mutual Investment Management Company LLC now owns 9,435 shares of the pharmaceutical company’s stock worth $812,000 after buying an additional 28 shares in the last quarter. Finally, Fisher Asset Management LLC increased its position in Vertex Pharmaceuticals by 1.1% in the third quarter. Fisher Asset Management LLC now owns 5,168 shares of the pharmaceutical company’s stock worth $451,000 after buying an additional 56 shares in the last quarter. 96.20% of the stock is currently owned by hedge funds and other institutional investors.

Vertex Pharmaceuticals Company Profile

Vertex Pharmaceuticals Incorporated is engaged in the business of discovering, developing, manufacturing and commercializing medicines for serious diseases. The Company operates in pharmaceuticals segment. Its business is focused on developing and commercializing therapies for the treatment of cystic fibrosis (CF) and advancing its research and development programs in other indications.

5 Day Chart for NASDAQ:VRTX

Receive News & Stock Ratings for Vertex Pharmaceuticals Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Vertex Pharmaceuticals Inc. and related stocks with our FREE daily email newsletter.